Acquisition of shares following the reinvestment of certain dividends accrued during the deferral period of the 2021 AstraZeneca Performance Share Plan award. of 73 shares at
AstraZeneca PLC
15 September 2026
15 September 2026
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that, on 14 September 2026, Dr Aradhana Sarin, Chief Financial Officer of the Company, acquired 73 of the Company's ordinary shares of $0.25 each (Ordinary Shares) following the vesting of certain dividend equivalent awards accrued in relation to her 2021 AstraZeneca Performance Share Plan (AZPSP) award.
The underlying 2021 AZPSP award vested to Dr Sarin on 17 August 2026 and was announced on 18 August 2026. Due to administrative processing timelines, the dividend equivalent awards relating to the Company's first interim dividend for 2026 were not included in that vesting. These dividend equivalent awards therefore vested separately on 14 September 2026. All other dividend equivalent units accrued during the performance and holding period were included within the 17 August vest.
Following the withholding of shares to satisfy certain tax obligations arising on vesting, Dr Sarin's beneficial interest in Ordinary Shares changed as detailed in the table below:
|
PDMR |
Position |
Ordinary Shares acquired
|
|
Aradhana Sarin |
Executive Director and Chief Financial Officer |
73 |
For tax purposes, the fair market value of an Ordinary Share at vest of the award was £114.60, being the closing price on the last trading day preceding the vesting of the 2021 AZPSP award.
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a) |
Name |
Aradhana Sarin |
||||
|
2 |
Reason for the notification |
|||||
|
a) |
Position/status |
Chief Financial Officer |
||||
|
b)
|
Initial notification /Amendment |
Initial notification |
||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
AstraZeneca PLC |
||||
|
b)
|
LEI |
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 |
||||
|
b)
|
Nature of the transaction |
Acquisition of shares following the reinvestment of certain dividends accrued during the deferral period of the 2021 AstraZeneca Performance Share Plan award. |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information - Aggregated volume - Price |
Not applicable - single transaction |
||||
|
e) |
Date of the transaction |
14 September 2026 |
||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.